Taking into account the contribution of microglia-mediated neuroinflammation in the pathophysiology of PD and the beneficial effects of caffeine and A2AR antagonists, one can hypothesize that pharmacologic blockade of A2AR might offer potential therapeutic benefit in PD at the level of motor alterations, neuroinflammatory response, and neuroprotection. This evidence concerns the gene ADORA2A and Parkinson disease.